Summary In order to evaluate the possible role of the proteolytic enzyme cathepsin B (cath B) in human non-small cell lung cancer (NSCLC) we examined cath B concentrations (cath B c ) and activities (cath B A ) in homogenates of 127 pairs of lung tumour tissues and corresponding nontumourous lung parenchyma. Total cath B activity (cath B AT ) and enzymatic activity of the fraction of cath B, which is stable and active at pH 7.5 (cath B A7.5 ) were determined by a fluorogenic assay using synthetic substrate Z-Arg-Arg-AMC. The immunostaining pattern of cath B was determined in 239 lung tumour tissue sections, showing the presence of the enzyme in tumour cells (cath B T-I ) and in tumour-associated histiocytes (cath B H-I ). The median levels of cath B AT , cath B A7.5 and cath B C were 5.6-, 3.2-and 9.1-fold higher (P < 0.001), respectively, in tumour tissue than in non-tumourous lung parenchyma. Out of 131 tissue sections from patients with squamous cell carcinoma (SCC), 59.5% immunostained positively for cath B, while among the 108 adenocarcinoma (AC) patients 48.2% of tumours showed a positive reaction. There was a strong relationship between the levels of cath B AT , cath B A7.5 , cath B C and cath B T-I in the primary tumours and the presence of lymph node metastases. Significant correlation with overall survival was observed for cath B T-I and cath B A7.5 (P < 0.01 and P < 0.05, respectively) in patients suffering from SCC. In these patients positive cath B in tumour cells (cath B T-I ) and negative cath B in histiocytes (cath B H-I ) indicated significantly shorter survival rate compared with patients with negative cath B T-I and positive cath B H-I (P < 0.0001). In contrast, in AC patients, both, positive cath B T-I and positive cath B H-I , indicated poor survival probability (P < 0.014). From these results we conclude that the proteolytic enzyme cath B is an independent prognostic factor for overall survival of patients suffering from SCC of the lung.
In recent years several studies have aimed at revealing the pathobiochemical functions of cathepsin B (cath B) in tumours and have led to the hypothesis that the enzyme is relevant for the progression of tumours, i.e. metastasis (reviewed by Berquin and Sloane, 1995; Elliot and Sloane, 1996; Lah and Kos, 1998; Yan et al, 1998) . There are a number of evidences, supporting this hypothesis: the levels of cath B in tumours were elevated above the levels in adjacent normal tissue as demonstrated for example in lung carcinoma (Trefz et al, 1989; Krepela et al, 1990; Sukoh et al, 1994a Sukoh et al, , 1994b Ebert et al, 1994; Ledakis et al, 1996; Werle et al, 1997a Werle et al, , 1997b , breast carcinoma (Lah et al, 1992 (Lah et al, , 1995a , colon carcinoma (Shuja et al, 1991) , head and neck carcinoma (Budihna et al, 1996) , oesophageal carcinoma (Hughes et al, 1998) and glioma (Rempel et al, 1994; Mikkelsen et al, 1995) . Elevated levels of the enzyme were also found in sera of tumour patients (Leto et al, 1997; Kos et al, 1997 Kos et al, , 1998 . Cath B was found concentrated at the invasive edges of colon carcinoma (EmmertBuck et al, 1994) . In vitro, tumour cells were found to be able to target cath B to the plasma membrane of tumour cells and to focal adhesion points relevant for motility to a greater extent than in normal cells (Rozhin et al, 1987; Sloane et al, 1987 Sloane et al, , 1994 Erdel et al, 1990; Strohmaier et al, 1997) . Increased secretion of the inactive proform or the active enzyme (Werle et al, , 1996 was sensitive to external stimuli, i.e. changes in pH or signal mediator 12(S)-HETE Honn et al, 1994; Ulbricht et al, 1996) . The balance between the enzyme and its physiological inhibitors seems to be disturbed in tumours (Knoch et al, 1994 ; reviewed by Calkins and Sloane, 1995; Lah et al, 1997) and finally, in vitro concerted inhibition of cath B and collagenases led to the most effective reduction of extracellular matrix degradation (Stonelake et al, 1997) .
The problem in defining a role of cath B in tumour progression arises from the fact that the enzyme is coded by a housekeeping gene, present in all, tumour and normal cells. Moreover, cath B was also found in tumour surrounding stromal cells and particularly in activated monocytes, which produce increased levels of cath B (Lah et al, 1995b) . The interplay between tumour and tumour surrounding cells, including autocrine and paracrine mechanisms, resulting in an overproduction of cath B by different cell types, is still not well understood (Opdenakker et al, 1992) . However, the appearance of the enzyme in tumours, if associated with malignancy and metastasis may be useful in prediction of Immunochemical analysis of cathepsin B in lung tumours: an independent prognostic factor for squamous cell carcinoma patients survival probability of patients with lung cancer after surgical treatment and thereby improving the effectiveness of post-operative therapy. Higashiyama et al (1991 Higashiyama et al ( , 1993 demonstrated increased expression of cath B in lung adenocarcinomas. Sukoh et al (1994a Sukoh et al ( , 1994b performed retrospective immunohistochemical studies, which showed that patients with tumours, strongly positive for cath B, had a significantly shorter overall survival compared with patients, which were negative for cath B. The authors recommended cath B as an independent prognostic marker in non-smallcell lung cancer (NSCLC), similar as concluded also by Inoue et al (1994) . We have also demonstrated a correlation between high native cath B activity at pH 6.0 (cath B AT ) and shorter survival probability of lung cancer patients . Recently, even more significant correlation with shorter survival was found for high activity of cath B-fraction, which was stable and active at pH 7.5 (cath B A7.5 ) (Werle et al, 1997b) . However, these studies were performed on relatively small population of patients and by a unifactorial methodological approach.
Here, we present an extended study on cath B activity and protein concentration in comparison with immunohistochemical (IHC) analysis of lung tumour sections of the same tumours. IHC analysis would have an advantage over immunochemical and activity analysis of tumour homogenates, due to the simplicity and less tumour tissue needed and would also allow for the discrimination between tumour cell and histiocytes associated cath B. Taken all results together, we demonstrated that IHC analysis of cath B offers a simple and independent prognostic factor for overall survival of patients with squamous cell carcinoma (SCC) of the lung.
PATIENTS, MATERIALS AND METHODS

Patients
We investigated two groups of patients for the levels of cath B. In the first group, comprising randomly selected 127 patients (15-81 years of age, mean 58.9 years, 104:23 male:female) we determined enzymatic activities and protein concentration, using an enzymelinked immunosorbent assay (ELISA). Immunohistochemical (IHC) analysis was performed in 92 out of these 127 patients and in an additional 147 patients (38-87 years of age, mean 61.0 years, 114:33 male:female), comprising therefore a total of 239 samples for IHC analysis. Cell typing of lung cancer was based on the (Hermanek and Sobin, 1987) . All patients included in this study were subjected to surgery, also 51 patients with pTNM IIIb and those 21 patients with pTNM IV, who undergo curative surgery due to incorrect preoperative clinical staging (cTNM) or due to individual favourable conditions. None of these patients were exposed to radiation therapy and received chemotherapy prior to surgery. After curative surgery patients in low stages were kept under surveillance, while patients in high stages additionally received adjuvant or palliative chemotherapy and/or radiation therapy (Manegold and Drings, 1998; Schraube et al, 1998) .
Cathepsin B activity (cath B AT , cath B A7.5 ) assays
Both assays were performed exactly as described in detail earlier (Werle et al, 1997a (Werle et al, , 1997b . Total cath B AT activity was measured with the substrate Z-Arg-Arg-AMC at pH 6.0. To receive the cath B fraction, which is stable and active at pH 7.5 (cath B A7.5 ), tissue homogenates were preincubated for 60 min at pH 7.5 and residual cath B activity was determined at the same pH. Specificity of the cath B fraction, which is stable and active at pH 7.5 (cath B A7.5 ) was verified by using the synthetic inhibitor CA-074.
Cathepsin B ELISA
Human cath B protein (cath B C ) in lung tissue homogenates was analysed using an ELISA (KRKA d.d., Novo mesto, Slovenia). The components were purified and characterized and the test was optimized as described (Kos et al, 1995 (Kos et al, , 1997 . The antibodies used for cath B ELISA recognize precursors, the mature form of the enzyme as well as enzyme-inhibitor complexes (Kos et al, 1995) . A microplate reader (SLT Rainbow, Austria) was used to measure absorbance. Cath B determined in ng ml -1 was standardized in ng mg -1 total protein of the tissue homogenates.
Determination of protein concentration
Protein concentration was determined according to Bradford (1976) . Bovine serum albumin was used as a standard.
Immunohistochemistry
Sections (3-5 µm) from formalin-fixed, paraffin-embedded tumour tissues were used for immunohistochemistry (IHC) (Hsu et al, 1981; Kayser and Gabius, 1997) . Briefly, lung tumour tissue sections were deparaffinized by xylene (2 × 5 min) and rehydrated through alcohol 99% (2 × 5 min), 96% (1 × 2 min), 70%
(1 × 2 min), 50% (1 × 2 min) to phosphate-buffered saline (PBS), pH 7.4 (3 × 3 min). After blocking: (i) endogenous peroxidase with 2% methanolic hydrogen peroxide for 15 min, (ii) nonspecific binding sites with 5% normal goat serum in PBS for 30 min at room temperature, tissue sections were rinsed in PBS (3 × 3 min) and incubated with sheep IgG anti-cath B (KRKA) 1:200 diluted in PBS containing 5% normal goat serum in a humid chamber at room temperature overnight. After washing in PBS (3 × 3 min), tissue sections were incubated with biotinylated rabbit anti-sheep antibody (Vector Laboratories, Serva Heidelberg, Figure 1 Immunohistochemical staining of cath B in tissue sections derived from (A) a squamous cell carcinoma (SCC) and (B) an adenocarcinoma (AC). Magnification × 256. Immunostaining was performed by using a polyclonal antibody directed against cath B. The colour was developed with 3,3′-diaminobenzidine and hydrogen peroxide. This SCC sample represents the pattern observed in the majority of SCC sections with strongest immunoreactivity of cath B at the periphery of tumour cell foci embedded in the stroma (arrows). Cath B distribution in AC is a granular cytoplasmatic staining (arrows). Histiocytes were identified at higher magnification and marked by arrowheads Germany) in PBS with 5% normal goat serum for 30 min and with the Vectastain ABC Reagent (Vector) for 30 min. Peroxidase activity was developed with 3,3′-diaminobenzidine tetrahydrochloide (0.3 mg ml -1 in 0.05 M Tris-buffer, pH 7.5), including 0.2% hydrogen peroxide for 10-15 min. Finally, tissue sections were light counterstained with 5% Harris's haematoxylin, dehydrated and mounted.
For IHC, the following control assays were performed: (i) incubation as in the assay, omitting the primary antibody; (ii) incubation omitting secondary antibody. Tissue sections were inspected by two independent pathologists (EK and KK). Both pathologists knew neither the diagnosis of the patients nor the result of the evaluation from each other. Both evaluations agree to 93%. Residual 7% were re-examined. The IHC scoring was performed separately for cath B in tumour cells (cath B T-I ) and cath B in histiocytes (cath B H-I ). Sections were classified into two groups according to the number of positively stained tumour cells or histiocytes and were considered positive for cath B T-I or cath B H-I when > 5% of stained cells were present. The intensity of staining was not considered as we observed that the intensity parallels the frequency (percentage) of immunopositive cells, similar as already reported (Castiglioni et al, 1994) .
Statistical analyses
To compare data of pairs of tumour and lung tissue, we used the two-tailed Wilcoxon's rank test. Differences in cath B levels in different groups of patients were tested by Mann-Whitney and Kruskal-Wallis test. The correlation between activities (cath B AT , cath B A7.5 ) and concentration (cath B C ) was calculated by nonparametric regression analysis and the significance of the Spearman rank correlation coefficient was evaluated by analysis of variance (ANOVA). Homogeneous variables, cath B AT , cath B A7.5 , cath B C , were recoded into two new groups based on the immunohistochemical evaluation cath B T-I : negative and positive respectively. For correlation between these two new groups of cath B AT , cath B A7.5 , cath B C and between the IHC scoring with different pTNM categories, Pearson's χ 2 and Fisher's exact test were used. Univariate analysis of survival probability was performed by Kaplan and Meier analysis (1958) , using the log-rank test for determination of statistical significance between the survival curves and multivariate analysis was performed using the Cox proportional hazard model (Cox, 1972) . The discrimination levels of differentiate between subgroups of patients were calculated by the Critlevel programme (Abel et al, 1984) . Various statistical packages (PC-Statistik, TOPSOFT, Hannover, Germany; Statistica, StatSoft, Hamburg, Germany) were applied.
RESULTS
Distribution of cathepsin B in lung tumours
We measured enzymatic activities of total cath B at pH 6.0 (cath B AT ) and stable, active fraction at pH 7.5 (cath B A7.5 ) as well as the concentration of the enzyme (cath B c ) in tissue extracts of 127 samples of NSCLC tumours and the corresponding nontumourous lung parenchyma. A summary of the data is given in Abel et al (1984) .
cath B A7.5 and the cath B c are 5.6-, 3.2-and 9.1-fold higher in tumour than in non-tumour lung parenchyma. The significance (P < 0.001) between tumour and normal tissue is high, although we observed certain overlapping in the activities and the concentration levels between tumour and non-tumour tissues. ]), considered as the upper limit of 'normal', we found an overlap with 52%, 80%, but only 7% of the respective tumour cases. Therefore, best discrimination between tumour and control tissue is indicated by increased cath B concentrations with a sensitivity of 93% and with a specificity of 99%.
For an IHC analysis (Table 2) we combined 92 out of the 127 samples where the cath B assays were performed with a second independent group of 147 samples, comprising the total of 239 NSCLC samples. According to histology, 131 of these patients suffered from squamous cell carcinoma (SCC) and 108 patients from adenocarcinoma (AC). Immunostaining for cath B was positive in 130 out of 239 of tissue sections (54.4%).
All these data were analysed with respect to tumour histology and pTNM-staging (as shown on Tables 1 and 2 ). There was no significant difference in the median levels of both types of cath B activities and cath B C between SCC and AC. We did not find a correlation with tumour size (pT) while cath B AT , cath B A7.5 and cath B C in primary tumours correlated very strongly with lymph node metastasis (pN status). These three parameters were significantly higher (P < 0.01, P < 0.05 and P < 0.01 respectively) in primary tumours of patients with lymph node metastases stage pN3 compared to the primary tumours without lymph node metastases (pN0). A steady increase of the median level of cath B A7.5 activity was also observed from pN0 over pN1, pN2 to pN3 tumours, which was close to significance (P = 0.073). Significant association between cath B C and pTNM stages was observed, as the median value of cath B C was significantly (P < 0.01) higher in pTNM IIIb than pTNM I tumours, although not in pTNM IV tumours. Table 2 shows that a clear positive immunoperoxidase reaction, associated with tumour cells, was observed among 131 SCC sections (59.5%) and 48.2% out of the 108 AC sections. However, there were significant differences in the staining patterns. In AC samples, the staining was distributed over the cytoplasm ( Figure  1B ) while in SCC samples, the intensity of immunoreactive cath B was strongest at the periphery of tumour cell foci embedded in non-tumour cell material ( Figure 1A) . Inflammatory cells such as histiocytes were always found associated with lung tumour cells and stained positively for cath B (cath B H-I ) in 102 out of 131 sections (77.9%) of SCC samples and in 75 out of 108 AC sections (69.5%). Cath B T-I was found to be more frequently positive in pT4-than in pT1-tumours and was more frequently positive in ΣpN1/pN2/pN3 than in pN0 tumours. Similar as for the total cath B concentration, positive labelling of tumour cell associated cath B (cath B T-I ) was observed in higher pTNM stages, as pTNM IIIb tumours were more frequently labelled than the pTNM I tumours (P < 0.05).
Correlation
The correlation's between evaluated cath B parameters are listed in Table 3 . In contrast to SCC we found in AC a positive correlation between all levels of cath B expression, cath B activities (cath B AT , cath B A7.5 ), cath B concentration and cath B T-I (P < 0.05, P < 0.01, and P < 0.1, respectively). In addition, the correlation in AC between cath B AT , cath B A7.5 and cath B concentration (both P < 0.001) was stronger compared to SCC (P < 0.05 and P < 0.1, respectively). In lung parenchyma of patients with SCC as well as with AC there was a significant correlation between cath B activities and cath B concentration (in all cases P < 0.001 and P < 0.001).
Association of cath B activities, concentrations and immunostaining with survival probability
For prognosis of patients with NSCLC the histological cell type and the stage of the disease are the most important prognostic factors used in the clinical routine. In order to evaluate prognostic value of cath B alone and in comparison with the established clinical prognostic factors, we performed univariate and multivariate survival analyses, respectively. Table 4 presents the significance of prognosis for cath B variables in comparison to the age and sex of the patients and for two different histologies of lung tumours. In tumour homogenates cath B AT and cath B C showed no significant prognostic value for 5-year survival (Table 4) . Noteworthy, for total population of NSCLC patients and for SCC patients cath B AT and cath B A7.5 were of prognostic significance in short observation periods of 6 months (NSCLC: cath B AT , P < 0.05) or 15 months (NSCLC and SCC: P < 0.05 and P < 0.05 respectively, data not shown). However, IHC analysis revealed that tumour cell associated cath B (cath B T-I ) was of prognostic significance for 5-year survival in the total population of NSCLC cancer patients (n = 239, P < 0.0001). Comparing the two different histologies cath B A7.5 and cath B T-I were also of prognostic significance for SCC patients (n = 65, P < 0.05; n = 131, P < 0.001, respectively), as illustrated in Figure 2 . In AC patients (n = 108, P < 0.05), only cath B T-I was significant. The IHC analysis also revealed that cath B in tumour associated histiocytes (cath B H-I ) in SCC and AC had different prognostic impact for survival (Figure 3 A,B) . SCC patients with negative cath B H-I had significantly shorter overall survival than SCC patients with positive cath B H-I (P = 0.028), while AC patients with positive cath B H-I had shorter survival rate (P < 0.05).
Univariate analyses
Furthermore, the combination of positive cath B in tumours and cath B in tumour associated histiocytes was also of prognostic relevance discriminating between additional subgroups of patients (Figure 3 C,D) . Nine out of 11 SCC patients with positive cath B T-I but negative cath B H-I died within 5 years (median survival time 13.3 months). In contrast, in the group of patients with negative cath B T-I and positive cath B H-I only 7 out of 37 patients died in this period. The median survival time in this group was 35 months (P < 0.0001). Patients with either positive cath B T-I and positive cath B H-I or negative cath B T-I and negative cath B H-I showed an intermediate value and were therefore grouped together (the median survival time was 20.7 months). In contrast to this, in AC patients, the best survival was observed in the group with negative cath B T-I and negative cath B H-I : 7 out of 26 patients died in 5 years; the median/mean survival time was 21.5/26.2 months respectively. The patients with positive cath B T-I and positive or negative cath B H-I were grouped together: 30 out of 51 patients died in 5 years, the median/mean survival time was 22.5/21.9 months respectively. The group with negative cath B T-I and positive cath B H-I showed a median/mean survival time of 24.5/21.9 months respectively. The probability of survival between these groups differed significantly (P = 0.034).
Multivariate analyses
In the multivariate analysis, only factors with a significant relationship to the survival probability found by the univariate analysis and independent from other factors were included. Thus, only two factors were considered: pTNM-staging and either cath B T-I as shown on Table 5 (Multivariate I, II, IV) or cath B A7.5 (Table 5 , Multivariate III). In the total population of NSCLC patients and in patients with SCC, only pTNM staging and cath B T-I or cath B A7.5 were significant for prognosis. Cath B had no impact on prognosis in patients with AC.
As demonstrated in Table 5 , pTNM-staging remained the best independent prognostic factor for patients with SCC and with AC. In addition, in SCC patients only, cath B T-I and cath B A7.5 were powerful independent prognostic factors.
To answer the question whether a combination of independent prognostic factors cath B T-I , cath B A7.5 and the pTNM-staging provide new information, patients were subdivided into two groups consisting of patients in a low pTNM-stage (pTNM I-IIIa) and a high pTNM-stage (pTNM IIIb and IV). Kaplan-Meier analyses showed that only 23 out of 86 patients ( Figure 4A -1 ] have a better overall survival probability compared to those patients above this cut-off point.
DISCUSSION
Previous studies on cath B in lung tumours, using either homogenates (Krepela et al, 1990; Sedo et al, 1991; Ebert et al, 1994; Ledakis et al, 1996; Werle et al, 1997a Werle et al, , 1997b or IHC analysis of cath B (Higashiyama et al, 1991 (Higashiyama et al, , 1993 Ozeki et al, 1993; Inoue et al, 1994; Sukoh et al, 1994a Sukoh et al, , 1994b , showed significantly enhanced expression of the enzyme at activity and protein levels in patients suffering from NSCLC. In this study, we clearly confirmed our earlier results as we found 9.1-fold increased cath B protein concentration as well as 5.6-fold increased total cath B activity and 3.2-fold increase in the fraction (-s-, 14/19) . A significant difference could be observed between SCC patients with high pTNM stage IIIb, IV and low cath B A7.5 (-v-, 5/7) compared with high cath B A7.5 (-s-, 6/7) of cath B activity, stable at pH 7.5 (Werle et al, 1997b) in tumour compared with normal lung tissue homogenates. Our data concerning enzyme expression revealed by IHC agree with previous investigations (Higashiyama et al, 1991 (Higashiyama et al, , 1993 Ozeki et al, 1993; Inoue et al, 1994; Sukoh et al, 1994a Sukoh et al, , 1994b demonstrating that more elevated levels of cath B were found in primary tumours, which invaded into lymph nodes. Noteworthy, fraction of cath B activity stable at pH 7.5 (cath B A7.5 ) steadily increased in more malignant lung tumours (from pN1 to pN3). These data strongly support the association of cath B with the pathobiochemical mechanism of tumour progression.
In relation to prognosis, the histological type and the tumour stage (TNM) of the lung tumours are considered as key factors relevant to prognosis for patients with NSCLC. However, new prognostic factors may still be needed to discriminate the patients with worse prognosis in low risk, e.g. low TNM-stage tumours. In this study, we found that tumour stage is still the best prognostic factor, but in addition, we demonstrated that immunohistochemical analysis of cath B, in particular tumour cell-associated cath B (cath B T-I ) is also a powerful independent prognostic factor in NSCLC patients. In contrast, cath B activities (cath B AT , cath B A7.5 ) and concentration (cath B C ), measured in tumour homogenates, had no prognostic relevance in the total population of NSCLC patients in a 5-year observation period. This is in contrast to the study by Ebert et al (1994) and Knoch et al (1994) , but similar to the recent study (Werle et al, 1997a ). The discrepancy with earlier studies is most likely due to longer observation period of 5 years in the present study. It is interesting to note that cath B AT and cath B A7.5 were of prognostic significance in shorter observation period of 6 months (cath B AT , P < 0.05; Ebert et al, 1994) and 15 months (both P < 0.05; unpublished data). When different histologies were considered separately, prognostic relevance of cath B AT and cath B A7.5 were found for patients suffering from SCC, already in shorter observation period (Werle et al, 1997a) . In contrast, in AC no prognostic impact of cath B AT , cath B A7.5 and cath B C was found in short (6, 15 and 24 months) and long (5 years) observation period.
Our findings agree with other univariate-and the multivariate survival analyses of cath B IHC analysis in tumour cells of adenocarcinoma (Sukoh et al, 1994a (Sukoh et al, , 1994b . Moreover, Ozeki et al (1993) further differentiated AC patients and demonstrated prognostic significance of cath B for lung AC of the Clara cell type only, but not for other subtypes of AC patients. The differences in these results may be due to different reagents and protocols used for IHC analysis and non-standardized scope of histological classifications of AC subtypes. It is known from large scale studies, that after surgery, the patients with SCC have a better overall survival probability than those with AC (Mountain, 1991). As indicated above, lung tumours of different histologies also differ with respect to cath B expression, distribution and relevance to prognosis. For example, in tumour homogenates, a fraction of cath B, stable at pH 7.5, cath B A7.5 was a prognostic factor for SCC patients, but not for AC patients (Werle et al, 1997a) . There was a significant correlation between cath B AT , cath B C and cath B T-I in AC, which was not found in SCC tumours. Immunohistochemical analysis of tumour cell associated cath B also revealed that the distribution of cath B over the cytoplasm of the tumour cell in AC was homogenous, while in SCC cath B was highly concentrated at the periphery of tumour cell foci, indicating that this fraction of cath B was possibly involved in tumour cell invasion. In these tumours (AC), a significant difference for patients with positive and negative expression of cath B in tumour cells (cath B T-I ) was found by the univariate analysis, but not in multivariate survival analyses using Cox regression model. Although our results are in close agreement to large-scale studies of Sukoh et al (1994a Sukoh et al ( , 1994b and Ozeki et al (1993) , there still exists a recent report from Mori et al (1997) , who could not demonstrate a significant correlation between cath B overexpression and overall survival probability of 31 lung cancer patients in TNM stage I. The discrepancy between these studies might be due to an insufficient number of patients in the study of Mori et al (1997) , distinct staining procedures, which included the use of divergent cath B antisera and different cut-off values for gradation of cath B stained tissue sections. However, cath B was also positive in 11 out of 12 SCC and 11 out of 15 AC tumours demonstrating an overexpression of cath B in lung tumours.
Immunohistochemistry also allows for a distinction between different cell types in tumour sections and we demonstrated a strong positive staining also in tumour-associated histiocytes, cath B H-I . In SCC patients, the presence of cath B in histiocytes had an impact on longer survival and this effect was stronger in cath B T-Inegative tumours. AC positive cath B H-I indicated worse prognosis, particularly in tumours with positive cath B T-I in tumour cells. These results indicate a possible role of cath B in tumour associated histiocytes. In general, the role of macrophages is still controversial. On one hand, activated macrophages are cytotoxic to tumour cells, as for example, interferon-gamma cured murine tumours in metastasis (Fidler, 1974) , although the regression of primary tumours was not observed. Similarly, in-situ activated macrophages are involved in host resistance to lymphoma metastasis probably by a production of nitric oxide (Umansky et al, 1995) . On the other hand, macrophages were found to directly stimulate tumour cell growth, inducing neovascularization and tissue dissolution. Furthermore somatic hybridization of tumour cells with the inflammatory macrophages was observed, resulting in highly metastatic variants of the original clones (Mantovani, 1990 ). We therefore suggest that different pathobiochemical mechanisms, involving cath B of macrophages, might be responsible for malignant progression of lung tumours of different histologies.
In conclusion, out of all cath B variables, only positive cath B T-I in NSCLC/SCC patients and high cath B A7.5 in SCC patients had high impact on prognosis in a 5-year observation period. Furthermore, in low pTNM stages (I, II and IIIa) overexpression of cath B T-I in NSCLC patients and high cath B A7.5 in SCC patients, indicated worse prognosis. Overexpression of cath B H-I in histiocytes might be useful in discriminating patients with higher risk for survival, depending on tumour histology.
